Number of HER2+ CTCs in AGC patients was reduced or even eliminated following HER2-targeted treatment (Figure 2C), which keeps in agreement with that reported on HER2+ breast cancer patients [21-26]. This evidence concerns the gene ERBB2 and breast carcinoma.